Selecta Biosciences (SELB) Stock Price, News & Analysis

Company Overview

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.88 to $1.26
• 52-Week Range: N/A
• Volume: 2.77 million shs
• Average Volume: 979,585 shs
• Market Capitalization: $136.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SELB Stock Analysis - Frequently Asked Questions

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) announced its quarterly earnings data on Thursday, August, 17th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.05. The business earned $5.25 million during the quarter, compared to analyst estimates of $9.90 million. Selecta Biosciences had a negative net margin of 72.04% and a negative trailing twelve-month return on equity of 44.13%.

When did Selecta Biosciences IPO?

Selecta Biosciences (SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Selecta Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), General Electric (GE), Pfizer (PFE), Palantir Technologies (PLTR) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/17/2023
• Today: 11/25/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SELB
• CUSIP: N/A
• CIK: 1453687
• Web: selectabio.com
• Phone: (617) 923-1400
• Fax: 617-924-3454
• Employees: 64
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $35.38 million
• Net Margins: -72.04%
• Pretax Margin: -73.23%
• Return on Equity: -44.13%
• Return on Assets: -22.00%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 4.18
• Quick Ratio: 4.18

Sales & Book Value

• Annual Sales: $110.78 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 9.91
• Book Value: $0.61 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 155,200,000
• Free Float: 106,780,000
• Market Cap: $136.76 million
• Optionable: Optionable
• Beta: 0.84